Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Beta-amyloid deposition in chronic traumatic encephalopathy Stein TD; Montenigro PH; Alvarez VE; Xia W; Crary JF; Tripodis Y; Daneshvar DH; Mez J; Solomon T; Meng G; Kubilus CA; Cormier KA; Meng S; Babcock K; Kiernan P; Murphy L; Nowinski CJ; Martin B; Dixon D; Stern RA; Cantu RC; Kowall NW; McKee ACActa Neuropathol 2015[Jul]; 130 (1): 21-34Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive mild traumatic brain injury. It is defined pathologically by the abnormal accumulation of tau in a unique pattern that is distinct from other tauopathies, including Alzheimer's disease (AD). Although trauma has been suggested to increase amyloid beta peptide (Abeta) levels, the extent of Abeta deposition in CTE has not been thoroughly characterized. We studied a heterogeneous cohort of deceased athletes and military veterans with neuropathologically diagnosed CTE (n = 114, mean age at death = 60) to test the hypothesis that Abeta deposition is altered in CTE and associated with more severe pathology and worse clinical outcomes. We found that Abeta deposition, either as diffuse or neuritic plaques, was present in 52 % of CTE subjects. Moreover, Abeta deposition in CTE occurred at an accelerated rate and with altered dynamics in CTE compared to a normal aging population (OR = 3.8, p < 0.001). We also found a clear pathological and clinical dichotomy between those CTE cases with Abeta plaques and those without. Abeta deposition was significantly associated with the presence of the APOE epsilon4 allele (p = 0.035), older age at symptom onset (p < 0.001), and older age at death (p < 0.001). In addition, when controlling for age, neuritic plaques were significantly associated with increased CTE tauopathy stage (beta = 2.43, p = 0.018), co-morbid Lewy body disease (OR = 5.01, p = 0.009), and dementia (OR = 4.45, p = 0.012). A subset of subjects met the diagnostic criteria for both CTE and AD, and in these subjects both Abeta plaques and total levels of Abeta1-40 were increased at the depths of the cortical sulcus compared to the gyral crests. Overall, these findings suggest that Abeta deposition is altered and accelerated in a cohort of CTE subjects compared to normal aging and that Abeta is associated with both pathological and clinical progression of CTE independent of age.|Adult[MESH]|Age Factors[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Amyloid beta-Peptides/*metabolism[MESH]|Apolipoprotein E4/genetics[MESH]|Athletes[MESH]|Athletic Injuries/epidemiology/genetics/metabolism/pathology[MESH]|Brain Injury, Chronic/epidemiology/genetics/metabolism/*pathology[MESH]|Brain/metabolism/*pathology[MESH]|Cohort Studies[MESH]|Comorbidity[MESH]|Humans[MESH]|Middle Aged[MESH]|Neurodegenerative Diseases/epidemiology/genetics/metabolism/*pathology[MESH]|Plaque, Amyloid/etiology/metabolism/pathology[MESH]|Severity of Illness Index[MESH]|Veterans[MESH]|War-Related Injuries/epidemiology/genetics/metabolism/pathology[MESH]|tau Proteins/*metabolism[MESH] |